Last updated: 2026-09-16 09:46:00. Prices reflect the latest pre-market trading data. Stock price data is sourced from Massive.
Anixa Biosciences, Inc. (ANIX) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $2,73, with a market capitalisation of $97,34M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $2,32 to $5,46. This page covers its latest market performance, valuation, price trends and company information.
$97,34M | |
$2,72 | |
$8,09 | |
$1,33 | |
$2,69 | |
20,00 | |
299,46K | |
-- | |
$5,46 | |
$2,32 | |
-- | |
-- |
Anixa Biosciences, Inc. (ANIX) is trading at $2,73 in pre-market trading as of 2026-09-16 08:36:00, up 1,45% ($0,04) from the previous close of $2,69
Pre-market trading shows how investors are pricing ANIX before the regular session opens. The current pre-market price is above the previous close, indicating positive early trading sentiment.
Over the past seven days, Anixa Biosciences, Inc. (ANIX) moved from $3,07 to $2,73, representing a decline of 11,11% ($0,34).
The stock traded between $2,66 and $3,20 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 401,27 thousand shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 13,0%
ANIX is currently trading at $2,73, placing it 13,0% of the way from its 52-week low of $2,32 to its 52-week high of $5,46. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Anixa Biosciences Inc is a biotechnology company developing therapies and vaccines focused on critical unmet needs in oncology. Its operations are organized into reportable segments comprising Cancer Vaccines, CAR-T Therapies, and Other. The Cancer Vaccines segment involves vaccines to treat and prevent breast and ovarian cancer, as well as additional cancer vaccines targeting intractable cancers, including high-incidence malignancies in lung, colon, and prostate. The CAR-T Therapies segment involves the development of liraltagene autoleucel (lira-cel), an ovarian cancer immunotherapy using chimeric endocrine receptor-T cell technology, developed at its subsidiary, Certainty Therapeutics, Inc. The Other segment consists of legacy operations, including limited patent licensing activities.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 4 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Anixa Biosciences, Inc. (ANIX) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.